Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines (Nasdaq: PRAX) granted restricted stock units covering 5,420 shares on May 1, 2026 to 21 new non-executive employees under its 2024 Inducement Plan.

Rhea-AI Summary

Praxis Precision Medicines (Nasdaq: PRAX) granted restricted stock units covering 5,420 shares on May 1, 2026 to 21 new non-executive employees under its 2024 Inducement Plan. Awards were made as inducements under Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest in four equal annual installments, subject to continued employment on each vesting date.

Argus May 6 session

+1.43% close to close Open Argus

Details

News Market Reaction – PRAX

In the May 6 session, PRAX gained 1.43%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine inducement RSU grants for 5,420 shares to 21 new non‑executive emp...

Analysis

This announcement details routine inducement RSU grants for 5,420 shares to 21 new non‑executive employees under the 2024 Inducement Plan, vesting over four years. It fits a pattern of administrative equity actions alongside more material catalysts, such as NDA acceptances for ulixacaltamide and relutrigine and positive EMBRAVE data. Investors tracking the story may focus more on upcoming clinical and regulatory milestones, overall share count trends, and how equity-based hiring supports the company’s CNS pipeline execution.

Key Figures

Current price: $337.61 Price change 24h: 4.14% 52-week range: $34.8925 – $355.9999 +5 more

Current price

$337.61

Before inducement grant news on 2026-05-05

Price change 24h

4.14%

Move prior to article publication

52-week range

$34.8925 – $355.9999

Price vs. 52-week low and high

Market cap

$9,029,240,059

Equity value prior to news

Inducement RSUs granted

5,420 shares

RSUs to new non-executive employees under 2024 Inducement Plan

New employees

21 employees

Recipients of inducement RSU awards

Plan year

2024 Inducement Plan

Equity plan used for inducement grants

Vesting schedule

4 annual installments

RSUs vest over four equal annual installments

Historical Context

5 past events · Latest: Apr 14

5 events

1. Apr 14

   NDA accepted

   24h Move

   +8.4%

   FDA accepted ulixacaltamide NDA with PDUFA date set for Jan 29, 2027.

2. Apr 13

   Data presentation

   24h Move

   +0.3%

   Expanded Phase 3 Essential3 data to be showcased at AAN 2026 meeting.

3. Apr 06

   Clinical results

   24h Move

   -0.1%

   Positive EMBRAVE Part A results for elsunersen in pediatric SCN2A DEE.

4. Apr 02

   Inducement grants

   24h Move

   -0.1%

   Inducement RSU awards covering 3,558 shares to new employees under 2024 plan.

5. Mar 30

   NDA priority review

   24h Move

   +16.6%

   FDA accepted relutrigine NDA with priority review and PDUFA date set.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock unit, nasdaq listing rule 5635(c)(4), equity awards

3 terms

restricted stock unit financial

"granted restricted stock unit awards covering an aggregate of 5,420 shares"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

nasdaq listing rule 5635(c)(4) regulatory

"as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

equity awards financial

"used exclusively for the grant of equity awards to individuals who were not previously employees"

Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on May 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 5,420 shares of its common stock to twenty-one new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.

About Praxis
Praxis Precision Medicines is a fully integrated, leading CNS precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.

Contacts:
Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452

Media Contact:
Dan Ferry
LifeSci Advisors
Daniel@lifesciadvisors.com
617-430-7576

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Praxis announce about inducement grants on May 1, 2026 (PRAX)?

Praxis granted restricted stock units totaling 5,420 shares to 21 new non-executive employees. According to the company, these awards were made under the 2024 Inducement Plan as inducements per Nasdaq Listing Rule 5635(c)(4).

How do the restricted stock units granted by Praxis (PRAX) vest?

The restricted stock units vest in four equal annual installments, conditioned on continued employment at each vesting date. According to the company, vesting is subject to the employee remaining employed through each scheduled vesting anniversary.

Who is eligible for awards under Praxis’s 2024 Inducement Plan (PRAX)?

The 2024 Inducement Plan is used exclusively for individuals who were not previously employees or who had a bona fide period of non-employment. According to the company, grants are intended as inducements material to entering employment.

Why did Praxis use Nasdaq Listing Rule 5635(c)(4) for these grants (PRAX)?

Praxis relied on Nasdaq Listing Rule 5635(c)(4) because the awards are inducements for newly hired employees. According to the company, the rule permits equity awards made as a material inducement to new employment.

Will the 5,420 shares granted by Praxis (PRAX) dilute existing shareholders?

The company reported awards covering 5,420 shares to new employees; any dilution depends on total outstanding shares and future issuances. According to the company, these awards were granted under the 2024 Inducement Plan and vest over four years.